Original articleImproved yeast delivery of fluconazole with a nanostructured lipid carrier system
Introduction
A variety of novel drug carrier systems have recently been proposed to improve the bioavailability and release of drugs [1]. These systems are aimed at maintaining local effects and enhancing drug accumulation in various strata of skin through liposomes or niosomes [2], gel formulation [3], lecithin-based organogel [4], hydrogel [5] or polymeric mucoadhesive films, [6] poly-lactic co-glycolic acid (PLGA) microspheres [7], solid lipid nanoparticles (SLNs) [8], [9], and nanostructure lipid carriers (NLCs) [10]. In particular, NLCs have emerged as a promising drug delivery system for pharmaceutical and cosmetic molecules, especially for the delivery of lipophilic compounds [11], [12], [13]. Briefly, NLCs are colloidal nanocarriers in the submicron range (40–1000 nm) composed of a solid lipid matrix and a liquid lipid [13]. They have several desirable advantageous such as low toxicity of constituents, and the ability to protect the incorporated drug from degradation by immobilization in the solid/liquid particle matrix [14]. Moreover, NLCs have overcome problems associated with SLNs, including limited drug loading, risk of gelation, and drug leakage during storage caused by lipid polymorphism [14].
Fluconazole (FLZ), a first-generation triazole, is a broad-spectrum anti-fungal agent that inhibits cytochrome P450-dependent 14α-lanosterol demethylation, a vital step in cell membrane ergosterol synthesis [15]. Fluconazole is active against all Candida species except for C. glabrata, which has acquired resistance to fluconazole, and C. krusie, which is resistant to the drug intrinsically [16], [17]. Despite its advantageous pharmacological activity, FLZ can cause several clinically significant side effects, including headache, hives, itching or skin rash, abdominal pain, and hematemesis [3]. While the prevalence and severity of side effects may be decreased by lowering the dose of FLZ, clinical efficacy may be reduced and resistance increased through this approach. This problem is important because FLZ is currently used for both prophylaxis and the treatment of broad spectrum infections of candidiasis, yet, the emergence of drug-resistant isolates continues to increase dramatically [18], [19], [20]. In response to this challenge, the use of new drug formulations and drug delivery systems to reduce resistance while maintaining or increasing clinical efficacy are urgently needed [21], [22]. While there is limited evidence regarding the effectiveness of FLZ loaded NLCs (FLZ-NLC) [1] on Candida albicans, the activity of FLZ-NLCs against a broad range of Candida species, including C. glabrata and C. krusie, has not yet been studied. To this end, the purpose of the present study was to estimate the clinical efficacy of FLZ-NLCs on FLZ-resistant strains of certain Candida species.
Section snippets
Materials
Fluconazole (FLZ, Pharmaceutica grade) was obtained from Arasto Pharmaceuticals Chemicals Inc. (Tehran-Iran). Compritol® 888 ATO (CO), Lipocire and Precirol® ATO 5 were supplied from Gattefossé (Saint-Priest, Cedex, France). Sabouraud dextrose agar (SDA), RPMI medium, stearic acid (SA), Oleic acid, Tween 80 (Tn80), Span 60 (Sn60) and Span 80 (Sn80) were purchased from Merck Co. (Germany). HPLC grade acetonitrile and methanol were supplied by the Merck (Germany). Morpholinepropanesulfonic acid
Screening of lipids
After evaluating the solubility of FLZ in the lipids, four lipids with different physicochemical properties were selected for the formulation of lipid nanoparticles, as listed in Table 1. Since no drug crystals were observed when FLZ and Compritol® 888 ATO or stearic acid were heated together (for all solid lipid:liquid lipid ratios), Compritol® 888 ATO and stearic acid were selected for production of NLCs. In contrast, FLZ was not completely soluble in the other lipids listed in Table 1.
Characterization of SLNs
The
Conclusions
In this study, we evaluated a novel delivery system for combating several Candida strains that exhibit different susceptibility to a conventional formulation of FLZ. An FLZ-loaded NLC consisting of stearic acid was successfully prepared by probe ultrasonication technique. Novel drug formulations may avoid drug recognition by efflux pump proteins, keeping the drug away from transporters. This study was the first to report the effectiveness of FLZ-NLCs as alternative delivery systems for FLZ on
Conflict of interest
There is no conflict of interest.
Acknowledgments
This research was financially supported by a Mazandaran University of Medical Sciences (MazUMS), Iran grant (No. 2013) given to Maryam Moazeni. The funder had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
References (39)
- et al.
Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis
Chem. Phys. Lipids
(2012) - et al.
Formulation optimization and in vitro skin penetration of spironolactone loaded solid lipid nanoparticles
Colloid Surf. B
(2015) - et al.
Time to overcome fluconazole resistant Candida isolates: solid lipid nanoparticles as a novel antifungal drug delivery system
Colloid Surf. B
(2016) - et al.
Spironolactone loaded nanostructured lipid carrier gel for effective treatment of mild and moderate acne vulgaris: a randomized double-blind, prospective trial
Colloid Surf. B
(2016) - et al.
Cosmetic applications for solid lipid nanoparticles (SLN)
Int. J. Pharm.
(2003) - et al.
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations
Adv. Drug Deliv. Rev.
(2002) - et al.
Nanostructured lipid matrices for improved microencapsulation of drugs
Int. J. Pharm.
(2002) - et al.
Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles
Int. J. Pharm.
(2009) - et al.
Development of solid lipid nanoparticles based controlled release system for topical delivery of terbinafine hydrochloride
Eur. J. Pharm. Sci.
(2013) - et al.
Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system
Colloid Surf. B
(2005)
Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification
Colloid Surf. B
Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release
Eur. J. Pharm. Biopharm.
Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery
Int. J. Pharm.
Lipid vesicles and other colloids as drug carriers on the skin
Adv. Drug Deliv. Rev.
Influence of nanocarrier type and size on skin delivery of hydrophilic agents
Int. J. Pharm.
Solid lipid nanoparticles: production, characterization and applications
Adv. Drug Deliv. Rev.
Regulation of multidrug resistance in pathogenic fungi
Fungal Genet. Biol.
Preparation and crystal characterization of a polymorph a monohydrate, and an ethyl acetate solvate of the antifungal fluconazole
J. Pharm. Sci.
Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs
Eur. J. Pharm. Sci.
Cited by (48)
Development and In-Vitro Evaluation of Eugenol-Based Nanostructured Lipid Carriers for Effectual Topical Treatment Against C. albicans
2024, Journal of Pharmaceutical SciencesEnhanced treatment in cutaneous dermatophytosis management by Zataria multiflora-loaded nanostructured lipid carrier topical gel: A randomized double-blind placebo-controlled clinical trial
2023, Journal of Drug Delivery Science and TechnologyChitosan film containing antifungal agent-loaded SLNs for the treatment of candidiasis using a Box-Behnken design
2022, Carbohydrate PolymersCitation Excerpt :However, another study has suggested that the nanoparticle size of the lipid particles facilitates close contact with the target yeast cells, potentially increasing drug penetration (Kelidari et al., 2017). Additionally, the hydrophobic surface of the SLN particles loaded in chitosan film may facilitate the drug's entry into target cells (Kelidari et al., 2017). As a result, the C-FS-films may prevent the drug from being effluxed by plasma membrane transport protein efflux pumps, a recognized route of drug resistance in fungal pathogens (Morschhäuser, 2010).
Methylene blue loaded solid lipid nanoparticles: Preparation, optimization, and in-vivo burn healing assessment
2022, Journal of Drug Delivery Science and TechnologyNanomedicines as an alternative strategy for Fungal disease treatment
2022, Advanced Nanomaterials for Point of Care Diagnosis and TherapyLipid nanoparticles and nanoemulsions exploited in the diagnosis and treatment of infectious diseases
2022, Nanotheranostics for Treatment and Diagnosis of Infectious Diseases